Protocol for the Wessex AsThma CoHort of difficult asthma (WATCH): a pragmatic real-life longitudinal study of difficult asthma in the clinic.
Asthma
Biobank
Cohort
Difficult Asthma
Longitudinal
Prospective
Severe Asthma
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
24 May 2019
24 May 2019
Historique:
received:
23
12
2018
accepted:
15
05
2019
entrez:
26
5
2019
pubmed:
28
5
2019
medline:
18
12
2019
Statut:
epublish
Résumé
Asthma is now widely recognised to be a heterogeneous disease. The last two decades have seen the identification of a number of biological targets and development of various novel therapies. Despite this, asthma still represents a significant health and economic burden worldwide. Why some individuals should continue to suffer remains unclear. The Wessex Asthma Cohort of Difficult Asthma (WATCH) is an ongoing 'real-life', prospective study of patients in the University Hospital Southampton Foundation Trust (UHSFT) Difficult Asthma service. Research data capture is aligned with the extensive clinical characterisation required of a commissioned National Health Service (NHS) Specialist Centre for Severe Asthma. Data acquisition includes detailed clinical, health and disease-related questionnaires, anthropometry, allergy and lung function testing, radiological imaging (in a small subset) and collection of biological samples (blood, urine and sputum). Prospective data are captured in parallel to clinical follow up appointments, with data entered into a bespoke database. The pragmatic ongoing nature of the WATCH study allows comprehensive assessment of the real world clinical spectrum seen in a Specialist Asthma Centre and allows a longitudinal perspective of deeply phenotyped patients. It is anticipated that the WATCH cohort would act as a vehicle for potential collaborative asthma studies and will build upon our understanding of mechanisms underlying difficult asthma.
Sections du résumé
BACKGROUND
BACKGROUND
Asthma is now widely recognised to be a heterogeneous disease. The last two decades have seen the identification of a number of biological targets and development of various novel therapies. Despite this, asthma still represents a significant health and economic burden worldwide. Why some individuals should continue to suffer remains unclear.
METHODS
METHODS
The Wessex Asthma Cohort of Difficult Asthma (WATCH) is an ongoing 'real-life', prospective study of patients in the University Hospital Southampton Foundation Trust (UHSFT) Difficult Asthma service. Research data capture is aligned with the extensive clinical characterisation required of a commissioned National Health Service (NHS) Specialist Centre for Severe Asthma. Data acquisition includes detailed clinical, health and disease-related questionnaires, anthropometry, allergy and lung function testing, radiological imaging (in a small subset) and collection of biological samples (blood, urine and sputum). Prospective data are captured in parallel to clinical follow up appointments, with data entered into a bespoke database.
DISCUSSION
CONCLUSIONS
The pragmatic ongoing nature of the WATCH study allows comprehensive assessment of the real world clinical spectrum seen in a Specialist Asthma Centre and allows a longitudinal perspective of deeply phenotyped patients. It is anticipated that the WATCH cohort would act as a vehicle for potential collaborative asthma studies and will build upon our understanding of mechanisms underlying difficult asthma.
Identifiants
pubmed: 31126281
doi: 10.1186/s12890-019-0862-2
pii: 10.1186/s12890-019-0862-2
pmc: PMC6534885
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
99Subventions
Organisme : Medical Research Council
ID : G0802804
Pays : United Kingdom
Organisme : MRF
ID : MRF_MRF-009-0003-RG-HAITC
Pays : United Kingdom
Références
Eur Respir J. 1999 May;13(5):1198-208
pubmed: 10414427
Am J Respir Crit Care Med. 2000 Dec;162(6):2341-51
pubmed: 11112161
Thorax. 2002 Oct;57(10):875-9
pubmed: 12324674
Eur Respir J. 2005 Sep;26(3):511-22
pubmed: 16135736
J Allergy Clin Immunol. 2007 Feb;119(2):405-13
pubmed: 17291857
Am J Respir Crit Care Med. 2008 Aug 1;178(3):218-224
pubmed: 18480428
Am J Respir Crit Care Med. 2010 Feb 15;181(4):315-23
pubmed: 19892860
Thorax. 2010 Sep;65(9):787-94
pubmed: 20805172
J Allergy Clin Immunol. 2011 Feb;127(2):382-389.e1-13
pubmed: 21195471
J Allergy Clin Immunol. 2011 Feb;127(2):355-60
pubmed: 21281866
Eur Respir J. 2012 Jul;40(1):55-60
pubmed: 22267763
Lancet. 2012 Aug 18;380(9842):651-9
pubmed: 22901886
N Engl J Med. 2013 Jun 27;368(26):2455-66
pubmed: 23688323
Eur Respir J. 2014 Feb;43(2):343-73
pubmed: 24337046
Lancet Respir Med. 2013 Oct;1(8):639-652
pubmed: 24461667
Clin Exp Allergy. 2014;44(5):724-35
pubmed: 24654674
Thorax. 2015 Apr;70(4):376-8
pubmed: 24917087
Chem Immunol Allergy. 2014;100:311-6
pubmed: 24925411
J Allergy Clin Immunol. 2014 Aug;134(2):287-94
pubmed: 24928647
PLoS One. 2014 Jul 24;9(7):e102987
pubmed: 25058007
Chest. 2015 Oct;148(4):870-876
pubmed: 25789861
Eur Respir J. 2015 Nov;46(5):1308-21
pubmed: 26357963
Thorax. 2016 Apr;71(4):339-46
pubmed: 26819354
J Allergy Clin Immunol. 2016 Jul;138(1):61-75
pubmed: 26851968
World Allergy Organ J. 2016 May 04;9:13
pubmed: 27195057
Clin Exp Allergy. 2016 Sep;46(9):1136-8
pubmed: 27574040
Respirology. 2017 Jan;22(1):53-60
pubmed: 27905186
Am J Respir Crit Care Med. 2017 May 15;195(10):1311-1320
pubmed: 27925796
Respir Res. 2016 Dec 15;17(1):165
pubmed: 27978840
Eur Respir J. 2017 Jan 3;49(1):
pubmed: 28049174
Eur Respir J. 2017 Feb 8;49(2):
pubmed: 28179442
J Allergy Clin Immunol Pract. 2018 Mar - Apr;6(2):545-554.e4
pubmed: 28866107
Eur Respir J. 1996 Apr;9(4):636-42
pubmed: 8726924
Am J Respir Crit Care Med. 1997 Sep;156(3 Pt 1):787-93
pubmed: 9309994